{
  "as_of": "2026-11-03",
  "track": "autoimmune",
  "source_url": "https://drugnews.com.tw/en/asia-autoimmune-leaders.html",
  "headers": [
    "rank",
    "asset",
    "inn",
    "originator",
    "country",
    "target",
    "mechanism",
    "highest_stage",
    "indications",
    "trial_ids",
    "overseas_rights_holder",
    "deal_date",
    "upfront",
    "total_value",
    "latest_event",
    "latest_event_date",
    "source_urls",
    "source_date"
  ],
  "rows": [
    [
      "1",
      "Peficitinib (ASP015K; Smyraf)",
      "peficitinib",
      "Astellas Pharma Inc.",
      "Japan",
      "JAK family",
      "Oral pan-JAK inhibitor",
      "Approved — Japan (2019-03)",
      "Rheumatoid arthritis",
      "NCT02308163 | NCT02305849",
      "Menarini Asia-Pacific — Taiwan; option for select Southeast Asian markets",
      "2023-09-13 (announcement)",
      "Not disclosed",
      "€5.5 million (upfront + milestones; royalties additional)",
      "Menarini announces Taiwan licensing agreement, with option for select Southeast Asian markets",
      "2023-09-13",
      "https://www.astellas.com/en/system/files/news/2019-03/190326_eg_pefi_approval_final.pdf | https://www.astellas.com/en/contact-us | https://www.menariniapac.com/en/news/2023/menarini-asia-pacific-enters-into-an-exclusive-licensing-agreement-with-astellas-to-commercialize-smyraf-in-taiwan-and-select-south-east-asian-markets.html | https://clinicaltrials.gov/study/NCT02308163 | https://clinicaltrials.gov/study/NCT02305849",
      "2023-09-13"
    ],
    [
      "2",
      "Delgocitinib (JTE-052; Corectim / Anzupgo)",
      "delgocitinib",
      "Japan Tobacco Inc.",
      "Japan",
      "JAK family",
      "Topical pan-JAK inhibitor",
      "Approved — Japan (2020-01); US (2025-07)",
      "Atopic dermatitis (Japan ointment); chronic hand eczema (US cream)",
      "NCT05355818 | NCT06004050",
      "LEO Pharma — topical dermatology worldwide excluding Japan",
      "2014-11",
      "Not disclosed",
      "Not disclosed",
      "FDA approves Anzupgo cream for adult moderate-to-severe chronic hand eczema",
      "2025-07-23",
      "https://www.jt.com/media/news/2020/pdf/20200529_E01.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/219155Orig1s000ltr.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219155Orig1s000OtherR.pdf | https://www.jt.com/investors/shareholders/pdf/2026/invite20260227_E.pdf | https://clinicaltrials.gov/study/NCT05355818 | https://clinicaltrials.gov/study/NCT06004050",
      "2025-07-23"
    ],
    [
      "3",
      "Telitacicept (RC18; Taiai)",
      "telitacicept",
      "RemeGen Co., Ltd.",
      "China",
      "BAFF (BLyS); APRIL",
      "TACI-Fc fusion protein inhibiting B-cell survival signals",
      "Approved — China (2021-03; conditional); full approval 2023-11",
      "Systemic lupus erythematosus; rheumatoid arthritis; generalized myasthenia gravis",
      "NCT03016013 | NCT05737160",
      "Vor Biopharma Inc. (Vor Bio) — worldwide excluding Greater China",
      "2025-06-25",
      "US$45 million cash + US$80 million warrants (US$125 million initial consideration)",
      "US$125 million initial consideration + up to US$4,105 million milestones; royalties additional",
      "RemeGen announces exclusive ex-Greater China license to Vor Bio",
      "2025-06-25",
      "https://www.remegen.com/?cid=93&v=listing | https://www.remegen.com/ | https://www.remegen.cn/uploadfile/2025/06/26/202506260918509042.pdf | https://clinicaltrials.gov/study/NCT03016013 | https://clinicaltrials.gov/study/NCT05737160",
      "2025-06-25"
    ],
    [
      "4",
      "Vunakizumab (SHR-1314; Andajing)",
      "vunakizumab",
      "Jiangsu Hengrui Pharmaceuticals Co., Ltd. / Suzhou Suncadia Biopharmaceuticals Co., Ltd.",
      "China",
      "IL-17A",
      "Humanized monoclonal antibody neutralizing IL-17A",
      "Approved — China (2024-08)",
      "Moderate-to-severe plaque psoriasis; active ankylosing spondylitis",
      "NCT04839016",
      "None reported",
      "—",
      "—",
      "—",
      "Suzhou Industrial Park reports approval for active ankylosing spondylitis",
      "2025-05-07",
      "https://www.hengrui.com/media/detail-721.html | https://www.sipac.gov.cn/szgyyqenglish/News/202505/241d45789537433bb1e6af590c21fda9.shtml | https://www.hengrui.com/images/investor/hk/2.%20Prospectus/2.%20Offer%20for%20Subscription%20%28EN%29.pdf | https://clinicaltrials.gov/study/NCT04839016",
      "2025-05-07"
    ],
    [
      "5",
      "Stapokibart (CM310; Kangyueda)",
      "stapokibart",
      "Keymed Biosciences Inc.",
      "China",
      "IL-4Rα",
      "Humanized monoclonal antibody blocking IL-4 and IL-13 signaling via IL-4Rα",
      "Approved — China (2024-09)",
      "Atopic dermatitis; chronic rhinosinusitis with nasal polyps; seasonal allergic rhinitis",
      "NCT05265923",
      "None reported",
      "—",
      "—",
      "—",
      "Company annual results report three approved stapokibart indications",
      "2025-03-26",
      "https://en.keymedbio.com/en/product.html | https://www.prnewswire.com/news-releases/keymed-biosciences-announces-annual-results-of-2024-302412143.html | https://www.keymedbio.com/en/aboutus.html | https://clinicaltrials.gov/study/NCT05265923",
      "2025-03-26"
    ],
    [
      "6",
      "Ivarmacitinib (SHR0302; Aisuda)",
      "ivarmacitinib",
      "Jiangsu Hengrui Pharmaceuticals Co., Ltd. / Reistone Biopharma",
      "China",
      "JAK1",
      "Selective JAK1 small-molecule inhibitor; oral and topical development",
      "Approved — China (2025-03)",
      "Active ankylosing spondylitis; rheumatoid arthritis; atopic dermatitis; severe alopecia areata",
      "NCT04481139 | NCT05470413",
      "Arcutis — topical dermatology in US, Japan, UK, EU and Canada; ARQ-255 development halted",
      "2018-01 (option agreement); 2019-12 (license exercised)",
      "US$0.4 million upfront + US$1.5 million option exercise",
      "Up to US$20.5 million development/regulatory + US$200 million sales milestones; initial payments and royalties additional",
      "Hengrui announces China approval for severe alopecia areata",
      "2025-06-30",
      "https://www.hengrui.com/media/detail-742.html | https://www.hkexnews.hk/listedco/listconews/sehk/2025/0630/2025063001988.pdf | https://www.hengrui.com/images/investor/hk/2.%20Prospectus/2.%20Offer%20for%20Subscription%20%28EN%29.pdf | https://www.sec.gov/Archives/edgar/data/1787306/000178730626000018/arqt-20251231.htm | https://clinicaltrials.gov/study/NCT04481139 | https://clinicaltrials.gov/study/NCT05470413",
      "2025-06-30"
    ],
    [
      "7",
      "Soficitinib (ICP-332)",
      "soficitinib",
      "InnoCare Pharma Limited / Beijing InnoCare Pharma Tech Co., Ltd.",
      "China",
      "TYK2 (JH1)",
      "Oral ATP-site TYK2 inhibitor",
      "Phase 3 — China (2024-11)",
      "Moderate-to-severe atopic dermatitis; other inflammatory skin diseases in earlier-stage trials",
      "NCT06775860",
      "None reported",
      "—",
      "—",
      "—",
      "Company Q3 results report primary endpoints met in atopic dermatitis Phase 3",
      "2026-10-26",
      "https://www.globenewswire.com/news-release/2026/10/26/3387927/0/en/innocare-reports-2026-q3-results-sustained-profitability-and-accelerating-globalization.html | https://www.innocarepharma.com/uploads/2026-03-26/2025-Annual-Report-CN-A.pdf | https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0428/2025042801073.pdf | https://clinicaltrials.gov/study/NCT06775860",
      "2026-10-26"
    ],
    [
      "8",
      "Fadeucravacitinib (ICP-488)",
      "fadeucravacitinib",
      "InnoCare Pharma Limited / Beijing InnoCare Pharma Tech Co., Ltd.",
      "China",
      "TYK2 (JH2)",
      "Oral allosteric TYK2 inhibitor",
      "Phase 3 — China (2025-03)",
      "Moderate-to-severe plaque psoriasis; cutaneous lupus and Sjögren syndrome in Phase 2",
      "NCT06842199",
      "None reported",
      "—",
      "—",
      "—",
      "Company Q3 results report primary endpoints met in psoriasis Phase 3",
      "2026-10-26",
      "https://www.globenewswire.com/news-release/2026/10/26/3387927/0/en/innocare-reports-2026-q3-results-sustained-profitability-and-accelerating-globalization.html | https://www.innocarepharma.com/uploads/2026-03-26/2025-Annual-Report-CN-A.pdf | https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0428/2025042801073.pdf | https://clinicaltrials.gov/study/NCT06842199",
      "2026-10-26"
    ]
  ],
  "row_sources": [
    [
      {
        "url": "https://www.astellas.com/en/system/files/news/2019-03/190326_eg_pefi_approval_final.pdf",
        "source_date": "2023-09-13"
      },
      {
        "url": "https://www.astellas.com/en/contact-us",
        "source_date": "2023-09-13"
      },
      {
        "url": "https://www.menariniapac.com/en/news/2023/menarini-asia-pacific-enters-into-an-exclusive-licensing-agreement-with-astellas-to-commercialize-smyraf-in-taiwan-and-select-south-east-asian-markets.html",
        "source_date": "2023-09-13"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT02308163",
        "source_date": "2023-09-13"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT02305849",
        "source_date": "2023-09-13"
      }
    ],
    [
      {
        "url": "https://www.jt.com/media/news/2020/pdf/20200529_E01.pdf",
        "source_date": "2025-07-23"
      },
      {
        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/219155Orig1s000ltr.pdf",
        "source_date": "2025-07-23"
      },
      {
        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219155Orig1s000OtherR.pdf",
        "source_date": "2025-07-23"
      },
      {
        "url": "https://www.jt.com/investors/shareholders/pdf/2026/invite20260227_E.pdf",
        "source_date": "2025-07-23"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT05355818",
        "source_date": "2025-07-23"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT06004050",
        "source_date": "2025-07-23"
      }
    ],
    [
      {
        "url": "https://www.remegen.com/?cid=93&v=listing",
        "source_date": "2025-06-25"
      },
      {
        "url": "https://www.remegen.com/",
        "source_date": "2025-06-25"
      },
      {
        "url": "https://www.remegen.cn/uploadfile/2025/06/26/202506260918509042.pdf",
        "source_date": "2025-06-25"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT03016013",
        "source_date": "2025-06-25"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT05737160",
        "source_date": "2025-06-25"
      }
    ],
    [
      {
        "url": "https://www.hengrui.com/media/detail-721.html",
        "source_date": "2025-05-07"
      },
      {
        "url": "https://www.sipac.gov.cn/szgyyqenglish/News/202505/241d45789537433bb1e6af590c21fda9.shtml",
        "source_date": "2025-05-07"
      },
      {
        "url": "https://www.hengrui.com/images/investor/hk/2.%20Prospectus/2.%20Offer%20for%20Subscription%20%28EN%29.pdf",
        "source_date": "2025-05-07"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT04839016",
        "source_date": "2025-05-07"
      }
    ],
    [
      {
        "url": "https://en.keymedbio.com/en/product.html",
        "source_date": "2025-03-26"
      },
      {
        "url": "https://www.prnewswire.com/news-releases/keymed-biosciences-announces-annual-results-of-2024-302412143.html",
        "source_date": "2025-03-26"
      },
      {
        "url": "https://www.keymedbio.com/en/aboutus.html",
        "source_date": "2025-03-26"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT05265923",
        "source_date": "2025-03-26"
      }
    ],
    [
      {
        "url": "https://www.hengrui.com/media/detail-742.html",
        "source_date": "2025-06-30"
      },
      {
        "url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0630/2025063001988.pdf",
        "source_date": "2025-06-30"
      },
      {
        "url": "https://www.hengrui.com/images/investor/hk/2.%20Prospectus/2.%20Offer%20for%20Subscription%20%28EN%29.pdf",
        "source_date": "2025-06-30"
      },
      {
        "url": "https://www.sec.gov/Archives/edgar/data/1787306/000178730626000018/arqt-20251231.htm",
        "source_date": "2025-06-30"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT04481139",
        "source_date": "2025-06-30"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT05470413",
        "source_date": "2025-06-30"
      }
    ],
    [
      {
        "url": "https://www.globenewswire.com/news-release/2026/10/26/3387927/0/en/innocare-reports-2026-q3-results-sustained-profitability-and-accelerating-globalization.html",
        "source_date": "2026-10-26"
      },
      {
        "url": "https://www.innocarepharma.com/uploads/2026-03-26/2025-Annual-Report-CN-A.pdf",
        "source_date": "2026-10-26"
      },
      {
        "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0428/2025042801073.pdf",
        "source_date": "2026-10-26"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT06775860",
        "source_date": "2026-10-26"
      }
    ],
    [
      {
        "url": "https://www.globenewswire.com/news-release/2026/10/26/3387927/0/en/innocare-reports-2026-q3-results-sustained-profitability-and-accelerating-globalization.html",
        "source_date": "2026-10-26"
      },
      {
        "url": "https://www.innocarepharma.com/uploads/2026-03-26/2025-Annual-Report-CN-A.pdf",
        "source_date": "2026-10-26"
      },
      {
        "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0428/2025042801073.pdf",
        "source_date": "2026-10-26"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT06842199",
        "source_date": "2026-10-26"
      }
    ]
  ],
  "records": [
    {
      "rank": "1",
      "asset": "Peficitinib (ASP015K; Smyraf)",
      "inn": "peficitinib",
      "originator": "Astellas Pharma Inc.",
      "country": "Japan",
      "target": "JAK family",
      "mechanism": "Oral pan-JAK inhibitor",
      "highest_stage": "Approved — Japan (2019-03)",
      "indications": "Rheumatoid arthritis",
      "trial_ids": "NCT02308163 | NCT02305849",
      "overseas_rights_holder": "Menarini Asia-Pacific — Taiwan; option for select Southeast Asian markets",
      "deal_date": "2023-09-13 (announcement)",
      "upfront": "Not disclosed",
      "total_value": "€5.5 million (upfront + milestones; royalties additional)",
      "latest_event": "Menarini announces Taiwan licensing agreement, with option for select Southeast Asian markets",
      "latest_event_date": "2023-09-13",
      "source_urls": "https://www.astellas.com/en/system/files/news/2019-03/190326_eg_pefi_approval_final.pdf | https://www.astellas.com/en/contact-us | https://www.menariniapac.com/en/news/2023/menarini-asia-pacific-enters-into-an-exclusive-licensing-agreement-with-astellas-to-commercialize-smyraf-in-taiwan-and-select-south-east-asian-markets.html | https://clinicaltrials.gov/study/NCT02308163 | https://clinicaltrials.gov/study/NCT02305849",
      "source_date": "2023-09-13"
    },
    {
      "rank": "2",
      "asset": "Delgocitinib (JTE-052; Corectim / Anzupgo)",
      "inn": "delgocitinib",
      "originator": "Japan Tobacco Inc.",
      "country": "Japan",
      "target": "JAK family",
      "mechanism": "Topical pan-JAK inhibitor",
      "highest_stage": "Approved — Japan (2020-01); US (2025-07)",
      "indications": "Atopic dermatitis (Japan ointment); chronic hand eczema (US cream)",
      "trial_ids": "NCT05355818 | NCT06004050",
      "overseas_rights_holder": "LEO Pharma — topical dermatology worldwide excluding Japan",
      "deal_date": "2014-11",
      "upfront": "Not disclosed",
      "total_value": "Not disclosed",
      "latest_event": "FDA approves Anzupgo cream for adult moderate-to-severe chronic hand eczema",
      "latest_event_date": "2025-07-23",
      "source_urls": "https://www.jt.com/media/news/2020/pdf/20200529_E01.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/219155Orig1s000ltr.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219155Orig1s000OtherR.pdf | https://www.jt.com/investors/shareholders/pdf/2026/invite20260227_E.pdf | https://clinicaltrials.gov/study/NCT05355818 | https://clinicaltrials.gov/study/NCT06004050",
      "source_date": "2025-07-23"
    },
    {
      "rank": "3",
      "asset": "Telitacicept (RC18; Taiai)",
      "inn": "telitacicept",
      "originator": "RemeGen Co., Ltd.",
      "country": "China",
      "target": "BAFF (BLyS); APRIL",
      "mechanism": "TACI-Fc fusion protein inhibiting B-cell survival signals",
      "highest_stage": "Approved — China (2021-03; conditional); full approval 2023-11",
      "indications": "Systemic lupus erythematosus; rheumatoid arthritis; generalized myasthenia gravis",
      "trial_ids": "NCT03016013 | NCT05737160",
      "overseas_rights_holder": "Vor Biopharma Inc. (Vor Bio) — worldwide excluding Greater China",
      "deal_date": "2025-06-25",
      "upfront": "US$45 million cash + US$80 million warrants (US$125 million initial consideration)",
      "total_value": "US$125 million initial consideration + up to US$4,105 million milestones; royalties additional",
      "latest_event": "RemeGen announces exclusive ex-Greater China license to Vor Bio",
      "latest_event_date": "2025-06-25",
      "source_urls": "https://www.remegen.com/?cid=93&v=listing | https://www.remegen.com/ | https://www.remegen.cn/uploadfile/2025/06/26/202506260918509042.pdf | https://clinicaltrials.gov/study/NCT03016013 | https://clinicaltrials.gov/study/NCT05737160",
      "source_date": "2025-06-25"
    },
    {
      "rank": "4",
      "asset": "Vunakizumab (SHR-1314; Andajing)",
      "inn": "vunakizumab",
      "originator": "Jiangsu Hengrui Pharmaceuticals Co., Ltd. / Suzhou Suncadia Biopharmaceuticals Co., Ltd.",
      "country": "China",
      "target": "IL-17A",
      "mechanism": "Humanized monoclonal antibody neutralizing IL-17A",
      "highest_stage": "Approved — China (2024-08)",
      "indications": "Moderate-to-severe plaque psoriasis; active ankylosing spondylitis",
      "trial_ids": "NCT04839016",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Suzhou Industrial Park reports approval for active ankylosing spondylitis",
      "latest_event_date": "2025-05-07",
      "source_urls": "https://www.hengrui.com/media/detail-721.html | https://www.sipac.gov.cn/szgyyqenglish/News/202505/241d45789537433bb1e6af590c21fda9.shtml | https://www.hengrui.com/images/investor/hk/2.%20Prospectus/2.%20Offer%20for%20Subscription%20%28EN%29.pdf | https://clinicaltrials.gov/study/NCT04839016",
      "source_date": "2025-05-07"
    },
    {
      "rank": "5",
      "asset": "Stapokibart (CM310; Kangyueda)",
      "inn": "stapokibart",
      "originator": "Keymed Biosciences Inc.",
      "country": "China",
      "target": "IL-4Rα",
      "mechanism": "Humanized monoclonal antibody blocking IL-4 and IL-13 signaling via IL-4Rα",
      "highest_stage": "Approved — China (2024-09)",
      "indications": "Atopic dermatitis; chronic rhinosinusitis with nasal polyps; seasonal allergic rhinitis",
      "trial_ids": "NCT05265923",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Company annual results report three approved stapokibart indications",
      "latest_event_date": "2025-03-26",
      "source_urls": "https://en.keymedbio.com/en/product.html | https://www.prnewswire.com/news-releases/keymed-biosciences-announces-annual-results-of-2024-302412143.html | https://www.keymedbio.com/en/aboutus.html | https://clinicaltrials.gov/study/NCT05265923",
      "source_date": "2025-03-26"
    },
    {
      "rank": "6",
      "asset": "Ivarmacitinib (SHR0302; Aisuda)",
      "inn": "ivarmacitinib",
      "originator": "Jiangsu Hengrui Pharmaceuticals Co., Ltd. / Reistone Biopharma",
      "country": "China",
      "target": "JAK1",
      "mechanism": "Selective JAK1 small-molecule inhibitor; oral and topical development",
      "highest_stage": "Approved — China (2025-03)",
      "indications": "Active ankylosing spondylitis; rheumatoid arthritis; atopic dermatitis; severe alopecia areata",
      "trial_ids": "NCT04481139 | NCT05470413",
      "overseas_rights_holder": "Arcutis — topical dermatology in US, Japan, UK, EU and Canada; ARQ-255 development halted",
      "deal_date": "2018-01 (option agreement); 2019-12 (license exercised)",
      "upfront": "US$0.4 million upfront + US$1.5 million option exercise",
      "total_value": "Up to US$20.5 million development/regulatory + US$200 million sales milestones; initial payments and royalties additional",
      "latest_event": "Hengrui announces China approval for severe alopecia areata",
      "latest_event_date": "2025-06-30",
      "source_urls": "https://www.hengrui.com/media/detail-742.html | https://www.hkexnews.hk/listedco/listconews/sehk/2025/0630/2025063001988.pdf | https://www.hengrui.com/images/investor/hk/2.%20Prospectus/2.%20Offer%20for%20Subscription%20%28EN%29.pdf | https://www.sec.gov/Archives/edgar/data/1787306/000178730626000018/arqt-20251231.htm | https://clinicaltrials.gov/study/NCT04481139 | https://clinicaltrials.gov/study/NCT05470413",
      "source_date": "2025-06-30"
    },
    {
      "rank": "7",
      "asset": "Soficitinib (ICP-332)",
      "inn": "soficitinib",
      "originator": "InnoCare Pharma Limited / Beijing InnoCare Pharma Tech Co., Ltd.",
      "country": "China",
      "target": "TYK2 (JH1)",
      "mechanism": "Oral ATP-site TYK2 inhibitor",
      "highest_stage": "Phase 3 — China (2024-11)",
      "indications": "Moderate-to-severe atopic dermatitis; other inflammatory skin diseases in earlier-stage trials",
      "trial_ids": "NCT06775860",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Company Q3 results report primary endpoints met in atopic dermatitis Phase 3",
      "latest_event_date": "2026-10-26",
      "source_urls": "https://www.globenewswire.com/news-release/2026/10/26/3387927/0/en/innocare-reports-2026-q3-results-sustained-profitability-and-accelerating-globalization.html | https://www.innocarepharma.com/uploads/2026-03-26/2025-Annual-Report-CN-A.pdf | https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0428/2025042801073.pdf | https://clinicaltrials.gov/study/NCT06775860",
      "source_date": "2026-10-26"
    },
    {
      "rank": "8",
      "asset": "Fadeucravacitinib (ICP-488)",
      "inn": "fadeucravacitinib",
      "originator": "InnoCare Pharma Limited / Beijing InnoCare Pharma Tech Co., Ltd.",
      "country": "China",
      "target": "TYK2 (JH2)",
      "mechanism": "Oral allosteric TYK2 inhibitor",
      "highest_stage": "Phase 3 — China (2025-03)",
      "indications": "Moderate-to-severe plaque psoriasis; cutaneous lupus and Sjögren syndrome in Phase 2",
      "trial_ids": "NCT06842199",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Company Q3 results report primary endpoints met in psoriasis Phase 3",
      "latest_event_date": "2026-10-26",
      "source_urls": "https://www.globenewswire.com/news-release/2026/10/26/3387927/0/en/innocare-reports-2026-q3-results-sustained-profitability-and-accelerating-globalization.html | https://www.innocarepharma.com/uploads/2026-03-26/2025-Annual-Report-CN-A.pdf | https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0428/2025042801073.pdf | https://clinicaltrials.gov/study/NCT06842199",
      "source_date": "2026-10-26"
    }
  ]
}